This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric abacavir/lamivudine/dolutegravir 60/30/5 mg dispersible tablets (pALD). Key questions addressed include benefits, potential side effects, price, and considerations for countries when considering transition to pALD.
Comments